Articles tagged with Cancer Medication
A new Canadian-made therapy, Urocidin, has shown promising results in treating superficial bladder cancer. Patients who received Urocidin became disease-free after one year, tolerating the treatment well.
Ray Johnston, a former NBA player, has survived acute promyelocytic leukemia thanks to experimental drug tamibarotene, which induced cancer cells to differentiate into mature cells. The rare form of leukemia is typically curable with current therapies but becomes more resistant and harder to treat upon relapse.
Researchers at UCSF have identified BCL6, a protein that leukemia cells use to survive treatment, as the basis for drug resistance. Targeting this protein may lead to more powerful cancer drugs and improved cure rates for children with leukemia.
A new study from the University of Michigan Comprehensive Cancer Center finds that half of prostate cancers have a genetic anomaly making them responsive to PARP inhibitors. These drugs are being tested in breast cancer patients and show promise in shrinking tumors and blocking cancer spread.
A new treatment combination of a PARP inhibitor with chemotherapy offered significant benefit in patients with metastatic colon cancer who had exhausted all standard therapies. The study found that the treatment controlled cancer growth for nearly six months in 23% of patients, with two experiencing a partial response.
A blood test counting circulating tumor cells is a reliable indicator of disease progression in patients with metastatic breast cancer. The test's predictive value remains consistent regardless of treatment type or sites of disease involvement.
Researchers at University of Rochester Medical Center have identified two genes, CDK6 and CDK4, that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment. The study found that targeting these genes may halt the growth of cancer cells.
Researchers have uncovered the detailed dynamics of the Epac2 protein switch, which plays a critical role in cAMP-mediated cell signaling. This finding holds promise for developing new therapeutic strategies specifically targeting this pathway to combat diseases like diabetes and cancer.
Researchers discover that celecoxib triggers liver cancer cell death by inhibiting a key protein, and combining it with chemotherapy drugs boosts effectiveness. The study suggests the possibility of a new treatment approach for liver cancer, which has a low five-year survival rate.
Researchers at UT Southwestern Medical Center have discovered a protein that guides blood vessel development and may lead to a treatment to starve cancer cells of nutrients. The protein, Rasip1, is specific to blood vessels and essential for their formation, making it a potential target for blocking tumor growth.
Researchers at Salk Institute discover a unique fasting pathway that turns up glucose production in the liver when blood sugar levels drop, providing a novel way to treat metabolic disease. Inhibiting histone deacetylases (HDACs) may help regulate blood glucose levels and prevent type II diabetes.
Yale researchers have found that a decoy receptor called serum sEGFR might limit the effectiveness of cancer 'smart drugs' like Cetuximab. This could explain why some patients do not respond to these treatments, even though the drug is supposed to target specific cancer cell growth drivers.
Researchers found that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer. Aromatase inhibitors, which block the production of estrogen, were shown to be effective in reducing tumor size and improving surgical outcomes.
A new study found that most blacks who don't call emergency services for stroke symptoms believe their symptoms are not serious enough or will resolve on their own. The survey suggests that education campaigns need to emphasize the importance of timely treatment and calling 911 immediately.
Researchers found that celecoxib induced an anti-tumor response at the molecular level, affecting genes involved in cell proliferation, apoptosis, and extracellular matrix biology. The study suggests that celecoxib may be efficient as a cancer treatment for people with primary invasive breast cancer.
Researchers discover natural compound acetyl resveratrol protects mice from radiation damage, potentially overcoming existing drug's limitations. The substance can be easily produced in large quantities and administered orally.
Researchers at Georgetown University Medical Center report that a drug developed to treat Ewing's Sarcoma may also prevent human prostate cancer from spreading. The agent, YK-4 279, was found to inhibit functions of proteins responsible for aggressive cell behavior in prostate cancer cells.
A novel potential drug-target for colorectal cancer treatment has been identified in a brain-derived protein. Brain-derived neurotrophic factor (BDNF) is present in greater amounts in colorectal tumors and may be involved in CRC progression and resistance to drugs.
A clinical trial at UT Southwestern Medical Center found that a biweekly dose of dactinomycin had a higher complete response rate than a weekly dose of methotrexate for treating low-risk gestational trophoblastic neoplasia. This regimen also required fewer treatment cycles and had lower toxicity.
A phase II study of selumetinib has shown promising results in patients with advanced biliary cancer, with significant tumor shrinkage and weight gain observed. The drug blocked the MEK protein, which is often damaged in biliary cancer cells, suggesting a new standard of care may be established
Researchers at U-M Comprehensive Cancer Center found that PARP inhibitors, currently used for breast and ovarian cancers, can also work against colorectal tumors with MRE11 gene mutations. The study suggests targeting these patients specifically could be a new therapeutic approach.
A Phase 3 clinical trial found that adding atrasentan to chemotherapy did not improve survival for patients with advanced prostate cancer. Patients who received the drug had similar progression-free survival as those given a placebo.
Researchers at Stanford University have developed a new biosensor microchip that can analyze thousands of protein-binding events simultaneously and continuously, potentially speeding up the process of drug development. The technology uses magnetic nanotags to detect interactions with greater sensitivity, enabling researchers to predict...
Researchers at UC San Diego School of Medicine have discovered a potential cancer biomarker in non-human sialic acid antibodies, which can also be used as a treatment to suppress tumor growth. The study found that patients with carcinomas have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain.
A biophysicist is developing a drug that targets Interleukin-6 (IL-6) to combat breast and prostate cancer. By blocking the protein's signaling pathway, researchers aim to prevent cellular inflammation and tumor growth.
A study by UCLA researchers found that ACE inhibitors may increase the risk of breast cancer recurrence in women who have had early-stage breast cancer. In contrast, beta blockers appeared to have a protective effect, and when used together with ACE inhibitors, may help mitigate this risk.
Researchers at Columbia University Irving Medical Center have developed an innovative yeast-based screening method to identify a possible new treatment for the fatal childhood disease NP-C. The approach, known as 'exacerbate-reverse', has shown promising results in repairing genetic pathways that exacerbate lethality in yeast models.
A new study by Ohio State University researchers shows that chronic inflammation can lead to cancer by stimulating the production of microRNA-155, which increases the rate of spontaneous gene mutations. This discovery suggests that reducing miR-155 levels may improve treatment for inflammation-related cancers.
Breast cancer patients whose cells use ketones and lactate as a food supply can be identified by gene profiling, predicting recurrence, metastasis, and poor clinical outcome. The researchers propose using this approach, called Metabolo-Genomics, to target oxidative mitochondrial metabolism with new anti-cancer drugs.
An experimental drug called NVP-BEZ235 blocks a crucial cancer cell signaling pathway, slowing ovarian cancer growth and increasing survival in an ovarian cancer mouse model. The drug also re-sensitizes resistant cancer cells to platinum chemotherapy, offering new hope for fighting drug resistance.
A study by University of Pennsylvania School of Medicine investigators shows that mice lacking a key protein develop squamous cell cancers resembling human disease, supporting novel therapies and early detection strategies. The findings settle a 20-year debate and prove the protein's role as a tumor-suppressor.
The National Institutes of Health has funded a study to develop an inhaled lung cancer treatment using the drug 5-azacytidine. Researchers at Albert Einstein College of Medicine aim to target premalignant lung cancer by reactivating genes that suppress tumors.
Researchers at NYU School of Medicine identified three novel small molecules that block a crucial cellular communication pathway regulating cancer growth. The finding could provide the basis for innovative therapies for colorectal cancer and other diseases associated with aberrations in this pathway.
Researchers discovered Camel-raised Nanobody agents that target breast cancer cells, offering a new approach to identifying effective treatments for individual patients. The 'Nanobodies' are robust, small, and easy to produce at low cost, making them a promising tool in the fight against breast cancer.
A new drug, DCC-2036, has shown potential in treating leukemia patients who have developed resistance to standard treatment. The study found that the drug was effective against human leukemia cells and prolonged survival in a mouse model of CML.
A newly discovered hybrid gene is found to play a role in some stomach cancers, potentially fueling tumor growth and survival. The CD44-SLC1A2 fusion gene may be at work in up to 2 percent of stomach cancers and could lead to improved therapies.
Researchers developed small-molecule MDM2 inhibitors that activate p53 protein, killing cancer cells while avoiding DNA damage. These new drugs shrank tumors in animal models of human cancer without significant side effects.
Researchers from UPCI and Pitt will present over 80 posters, talks, and tutorials on various cancer studies, including the effects of immunomodulatory derivatives on blood cell production pathways and the role of inflammatory mediators in immune system dysfunction. Additionally, they will discuss the development of vaccines targeting p...
A Purdue University biochemist has created a nanopolymer that can be coated with drugs and then removed to determine which proteins the drug has entered. This development may help reduce side effects associated with cancer drugs by allowing for more targeted drug delivery.
Researchers at Fox Chase Cancer Center have developed a screen to identify proteins that work with histone deacetylases and DNA methyltransferases to repress gene expression. The method revealed 128 factors involved in regulating gene expression, potentially leading to broader cancer therapies
Researchers at the University of Pennsylvania School of Medicine have found a novel drug combination that successfully treats advanced cancer patients. The temsirolimus-hydroxychloroquine combination was shown to halt tumor growth in two-thirds of patients, including those with melanoma, colorectal, and head and neck cancers.
Researchers at Queen's University Belfast have developed a new drug that prevents tumor growth by cutting off their blood supply, showing promise for treating prostate and breast cancers. The treatment targets tumor angiogenesis using an entirely different pathway than existing therapies.
Researchers found that men using digoxin had a 24% lower risk of prostate cancer. The study also identified other approved drugs with anti-prostate cancer properties, paving the way for further research and potential new treatments.
Researchers sequenced whole genomes of tumors from 50 breast cancer patients and compared them to healthy cells, finding over 1,700 unique mutations. The study highlights the complexity of cancer genomes and offers new insights into personalized medicine.
The American Association for Cancer Research is prioritizing clinical trials to advance cancer treatment and prevention. Researchers presented findings on basal cell cancer and lung cancer, highlighting the potential of biomarkers and hedgehog pathway inhibitors. New discoveries aim to improve patient outcomes and reduce side effects.
PBS-Bio presents two abstracts at the AACR conference, showing how drugs UNBS1450 and NDC-1308 affect cancer cells. The technology allows real-time measurement of cellular responses to drugs, identifying potential biomarkers for patient selection and drug development.
Researchers will study how tumor cells avoid immune detection, enabling cancer spread, and test whether modifying the environment can activate unresponsive immune cells against cancer. The grant enables visualization of tumor and immune cell interactions in real-time.
A new therapeutic target for lung cancer has been identified by researchers at Seoul National University. The variant of the protein AIMP2 is highly expressed in lung cancer cells and has been shown to compromise the tumor-suppressing activity of AIMP2, suggesting its potential as a new treatment option.
Researchers at the University of Michigan have developed a new drug called AT-406 that effectively targets proteins blocking normal cell death, leading to tumor cell death while sparing normal cells. The drug has shown promising results in animal models, shrinking tumors with minimal side effects.
Researchers develop innovative strategy to target tumor metabolism, block energy production required for malignant cancer growth, delaying tumor volume and spread. The treatment combines ultrasound-guided intra-tumoral delivery of a potent drug with imaging guidance to minimize healthy tissue exposure.
A new nanodrug breaks down barriers to attack breast cancer cells by carrying multiple drugs that accumulate in tumor cells and strike cancer-specific molecular targets. This targeted approach shows promise as a more effective treatment method than standard treatment, with the potential to be tailored for various disorders.
Scientists have discovered stapled peptides that can target proteins involved in colon cancer and asthma. These peptides, which are not small molecules, inhibit activity of key proteins in the body, offering a new frontier in medicine.
A Phase II trial of Gleevec (imatinib) has shown acceptable safety and tolerability, with hints of efficacy in treating diffuse scleroderma. The drug improved skin scores by 22% and forced vital capacity scores by 6.4% after 12 months of therapy.
The American Association for Cancer Research (AACR) is honoring two renowned cancer researchers, Helen Blau and Nathanael Gray, for their groundbreaking contributions to the field. Helen Blau's work on regenerative medicine and cellular plasticity has led to new approaches in modeling diseases and regenerating damaged tissues.
The FDA is considering new rules to speed up confirmatory trials of drugs granted accelerated approval, following a review that found six indications remained on the market without confirmation. The median time between accelerated and regular approval was 3.9 years, with some drugs remaining on the market for over 10 years.
The American Association for Cancer Research and the Landon Foundation will present three INNOVATOR Awards to recognize emerging mid-career researchers. The awards support innovation in cancer prevention, international collaboration, and personalized medicine research.
Susan Band Horwitz, a renowned molecular pharmacologist, receives the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Her pioneering work on paclitaxel has led to significant advancements in cancer treatment, particularly in ovarian, breast, and lung carcinomas.
Pier Paolo Pandolfi has made significant contributions to cancer research, particularly in the area of leukemia treatment. His work on mouse models and chromosomal translocations has led to the development of novel therapeutic strategies, making APL a curable disease.
Researchers at UCLA developed a 'roadmap' of complex signaling processes in cancer that could lead to new methods for diagnosing and overcoming drug resistance. The study identifies points of susceptibility that can be targeted by 'cocktail' therapies to prevent drug resistance.
Researchers discover PinX1's role in preventing chromosome instability and cancer initiation. Low levels of PinX1 contribute to cancer development by activating telomerase, a process linked to human cancers with genetic alterations at chromosome 8p23.